Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARD6562, Docetaxel · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ARD6562, Docetaxel | DRUG | - |
Inclusion Criteria: * Men with prostate adenocarcinoma with at least one metastatic lesion which is measurable and who progressed after prior hormonal therapy. Exclusion Criteria: * 1.Body temperature \> 38 degree centigrade. * 2.Prior radiotherapy to \> 25% of bone marrow. * 3.Prior isotope ther...
ARD6562 is a small molecule being studied for the treatment of prostatic neoplasms, specifically metastatic hormone refractory prostate cancer. It is used in combination with prednisolone. The drug is currently in Phase 2 clinical development and is considered investigational.
ARD6562 is being developed by Sanofi, a company traded under the ticker SNY. The drug is in Phase 2 clinical development for the treatment of prostatic neoplasms.
ARD6562 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 clinical trial has been completed.
ARD6562 has one completed clinical trial, identified as NCT00291005. This was a Phase 2, open-label, non-comparative trial in metastatic hormone refractory prostate cancer, combining the drug with prednisolone. The trial enrolled 42 male participants in Japan.
ARD6562 is also known as docetaxel. It is a small molecule being developed by Sanofi for the treatment of prostatic neoplasms, specifically metastatic hormone refractory prostate cancer.